Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Assets (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Non-Current Assets data on record, last reported at $1.6 million in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 98.67% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $180.0 million, down 28.79%, while the annual FY2025 figure was $1.6 million, 98.67% down from the prior year.
  • Non-Current Assets reached $1.6 million in Q4 2025 per SNDX's latest filing, down from $22.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $121.8 million in Q4 2024 and bottomed at $504000.0 in Q2 2021.
  • Average Non-Current Assets over 5 years is $27.7 million, with a median of $16.2 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: skyrocketed 2707.54% in 2022, then crashed 98.67% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $1.3 million in 2021, then surged by 490.8% to $7.4 million in 2022, then surged by 329.58% to $32.0 million in 2023, then skyrocketed by 280.45% to $121.8 million in 2024, then plummeted by 98.67% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $1.6 million in Q4 2025, $22.0 million in Q3 2025, and $64.5 million in Q2 2025.